FTC approves final order relating to Endo acquisition of Par Pharma

Following a public comment period, the Federal Trade Commission has approved a final order settling charges that the $8 billion merger between Endo International (Nasdaq: ENDP) and privately-held Par Pharmaceuticals would likely be anticompetitive.

Under the order (The Pharma Letter September 28), the companies are required to sell Endo’s US rights and assets for generic glycopyrrolate tablets, which are used with other drugs to treat certain types of ulcers, and generic methimazole tablets, which are used to treat the body’s production of excess thyroid hormone to Rising Pharmaceuticals.

The Commission vote approving the final order was 4-0.